STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System

Stereotaxis STXS recently announced that physicians at Erasmus University Medical Center in Rotterdam successfully performed the first procedures in the Netherlands using its Genesis Robotic Magnetic Navigation (RMN) System.

The adoption of Genesis at a leading European cardiac center underscores the growing clinical confidence in robotic solutions for treating complex arrhythmias. With tens of millions worldwide suffering from arrhythmias, the introduction of Genesis represents a significant step toward expanding access to advanced treatment. The collaboration also reflects Stereotaxis’ continued progress in strengthening clinical partnerships while broadening the reach of its robotic innovations.

Likely Trend of STXS Stock Following the News

Following the announcement, the company's shares gained 2.5% at yesterday’s market closing. Shares have rallied 26.3% in the year-to-date period against the industry’s 11.4% decline. The S&P 500 has gained 14.4% in the same time frame.

In the long run, this milestone supports STXS by showcasing Genesis at a leading European heart center, which can encourage broader adoption among hospitals worldwide. More installations mean recurring revenue from system usage and related products, while also strengthening Stereotaxis’ reputation as a trusted innovator in robotic cardiac care, positioning the company for steady growth and long-term value creation.

Meanwhile, STXS currently has a market capitalization of $255.9 million.

More on the News

Erasmus University Medical Center in Rotterdam, one of Europe’s leading cardiac centers, has become the first in the Netherlands to perform procedures using Stereotaxis’ RMN System. Physicians at the hospital praised Genesis for its speed, responsiveness, and precision, especially when paired with the company’s MAGiC catheter, noting clear improvements in safety and care for complex arrhythmia patients, including children and those with congenital heart conditions.

Erasmus MC is no stranger to Stereotaxis’ technology, having already completed over 4,500 procedures using robotic magnetic navigation. With arrhythmias affecting tens of millions globally and carrying serious health risks if untreated, the successful introduction of Genesis at such a renowned institution highlights both the clinical value and commercial potential of STXS’ solutions. This strengthens the company’s credibility with physicians and hospitals worldwide, while also supporting its mission to modernize cardiac care through robotic precision.

More on the STXS’ Genesis RMN System

The Genesis RMN System represents Stereotaxis’ next-generation robotic magnetic navigation technology for cardiac electrophysiology labs. Compared to its predecessor (Niobe), Genesis uses smaller magnets that rotate along their center of mass and are mounted on flexible robotic arms, which gives physicians far more precision and responsiveness. It is significantly faster, enabling quicker procedures and potentially increased throughput. Also, the system is designed to be smaller and lighter, which improves patient accessibility during procedures, optimizes workspace in electrophysiology (EP) labs and can reduce infrastructure burden.

On the regulatory and adoption front, Genesis RMN is already cleared for use in multiple geographies, including FDA clearance in the United States, CE-mark in Europe and recent regulatory approval in China. This growing base of clinical use helps generate data and physician experience, which in turn supports further adoption. It also means more recurring revenue from usage and maintenance, as well as from compatible catheters, such as the MAGiC line. The safety, reliability, and precision improvements are key for hospitals evaluating capital investment in EP lab robotics.

STXS’s Zacks Rank & Stocks to Consider

STXS carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. WST, Medpace Holdings, Inc. MEDP and Envista NVST.

West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.

Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.

Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).

Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research